Alexander VM, et al. – Here, researchers find out if there is a survival or cost benefit dependent on detection strategy of recurrent ovarian cancer (ie, imaging, physical examination findings, report of symptoms, or rising cancer antigen 125 [CA–125] levels). The outcomes show minimal differences in progression–free survival (PFS) and statistically insignificant differences in overall survival (OS), depending on detection method. Notably, black patients with Medicaid presented most often with symptomatic recurrences, which surprisingly did not influence patient OS and PFS; and interestingly, private or self–pay insurance was related to decreased OS among black patients. From the cost analysis, they estimate that the most cost–effective surveillance strategy for the first year costs $9.2 million annually and includes office visit biannually, biannual CA–125 levels, and annual asymptomatic imaging.